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SKIM LEAN aims at exploiting Electronic Health Records (EHRs) to integrate knowledge
derived from routine laboratory tests with background analysis of clinical databases,
for the identification and early referral to specialist care, where appropriate, of patients
with hypercholesterolemia, who may be inadequately controlled according to their
cardiovascular (CV) risk level. SKIM LEAN addresses gaps in care that may occur through
the lack of coordination between primary and specialist care, incomplete adherence to
clinical guidelines, or poor patient’s compliance to the physician’s prescriptions because
of comorbidities or drug side effects. Key project objectives include: (1) improved
health professionals’ competence and patient empowerment through a two-tiered
educational website for general practitioners (GPs) and patients, and (2) implementation
of a hospital-community shared care pathway to increase the proportion of patients at
high/very-high CV risk (Familial Hypercholesterolemia, previous CV events) who achieve
target LDL cholesterol (LDL-C) levels. Thanks to a close collaboration between clinical
and information technology partners, SKIM LEAN will fully exploit the value of big data
deriving from EHRs, and filter such knowledge using clinically-derived algorithms to
risk-stratify patients. Alerts for GPs will be generated with interpreted test results. GPs
will be able to refer patients with uncontrolled LDL-C within the shared pathway to the
lipid or secondary prevention outpatient clinics of NIG hospital. Metrics to verify the
project achievements include web-site visits, the number of alerts generated, numbers
of patients referred by GPs, the proportion of secondary prevention patients who achieve
LDL-C <100 mg/dl or a >50% decrease from baseline.
Keywords: hypercholesterolemia, high cardiovascular risk, cardiovascular risk, LDL-cholesterol, electronic health
records
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INTRODUCTION
Ischemic heart disease and stroke are the world’s largest causes
of death, accounting for a combined 15 million deaths in 20151
Ischemic heart disease has been estimated to be the leading cause
of disability in Europe, accounting for approximately 10% of total
disability-adjusted life years. High plasma concentrations of low-
density lipoprotein cholesterol (LDL-C) showed a strong linear
relationship with the incidence of cardiovascular disease (CVD)
(Castelli et al., 1992; Ference et al., 2017). Thus, as demonstrated
by multiple randomized controlled trials, reduction of LDL-
C is crucial for CVD prevention (Baigent et al., 2005,
2010). However European studies have highlighted extensive
underdiagnosis and undertreatment of hypercholesterolaemia,
particularly in some special populations, such as subjects
with genetically-determined hypercholesterolemia (i.e., familial
hypercholesterolemia), patients with knownCVD (i.e., secondary
prevention), diabetes or chronic kidney disease (CKD), as well as
patients with high levels of individual risk factors (Nordestgaard
et al., 2013; Reiner et al., 2013).
Familial hypercholesterolaemia (FH) is a monogenic
autosomal dominant inherited disorder characterized by
excessively high plasma levels of LDL-C from birth, due to a
defect in the LDL receptor pathway. Without early detection
and treatment, individuals with FH are at significantly elevated
risk of premature ischemic heart disease due to accelerated
onset of atherosclerosis. In the literature reported FH prevalence
rates range from 1:200 to 1:500 (Hopkins, 2003; Nordestgaard
et al., 2013; Schmidt et al., 2017). FH is relatively easy to
detect and treat, but currently only an estimated 10% of FH
cases are detected (Nordestgaard et al., 2013). Screening for
FH through electronic health records has been suggested to
represent the most systematic and cost-effective approach, with
a high potential for integration into clinical practice. Studies
in the primary care setting (Guglielmi et al., 2016; Safarova
et al., 2016; Troeung et al., 2016; Vickery et al., 2017) have
been conducted using automated detection algorithms based
on laboratory lipid profile coupled to ICD coding and/or
prescription of lipid lowering medications and Natural Language
Processing for family history and presence of FH stigmata
on physical examination, against a gold standard of modified
Dutch Lipid Clinic Network diagnostic criteria. Estimates from
Australia, Olmstead County in Minnesota US and Italy reported
a prevalence of probable/definite FH ranging from 1:146 to 1:556.
Aref-Eshghi et al. applied a similar approach to the Canadian
Primary Care Sentinel Surveillance Network database, and found
that combining the history of medication therapy with abnormal
lipid levels resulted in the best algorithm for the identification of
subjects with dyslipidemia from electronic medical records, since
the use of ICD diagnostic codes in primary care databases yielded
a high number of false negative results. These authors did not
however stratify their findings according to CV risk (Aref-Eshghi
et al., 2017).
The need for a better control of cholesterol levels in Italy
has been recently documented in an electronic registry in the
1http://www.who.int/mediacentre/factsheets/fs310/en/
primary care setting matched with administrative data on the use
of medicines (Mazzaglia et al., 2009), in national studies (Poli
et al., 2011, 2012) and international surveys (Reiner et al., 2013,
2016).
In a 2014 analysis of the national Health Search primary
care database (Mazzaglia et al., 2009), the overall prevalence of
dyslipidemia in the general practice setting was 15.8% (16.4%
in women, 15.2% in men), increased with age and peaked at
34.1% between 66 and 75 years. Among subjects with diagnosed
dyslipidemia, only 29.2% had LDL-C levels <100 mg/dl.
Statins represent an important share of drug expenses in Italy
with a Defined Daily Dose of 67.6/1000 residents. Statins, the
main cholesterol-lowering agents, are prescribed for primary
prevention in 75% of cases, while only 56% of patients with a
previous CV event or diabetes are on statins; however, overall
treatment adherence rate is as low as 47%2.
The CHECK study analyzed CV risk as defined by the CUORE
algorithm, derived by the National Health Institute from Italian
cohorts3, in a primary care population of 5,456 subjects. CHECK
documented a 24% prevalence of high-risk or very high-risk
profiles (33% men, 16% women). Cholesterol levels beyond the
desirable target were found in approximately one third of the
overall cohort, 25% of diabetics and 26% of secondary prevention
patients. Based on CHECK findings, almost 5 million Italians
were estimated to need to reduce their LDL-C by over 37.5%
(Poli et al., 2011). As for secondary prevention, the EuroAspire
Surveys III (Reiner et al., 2013) and IV (Reiner et al., 2016) have
documented in Italy LDL-C levels >100 mg/dl in 54.3% and
42.2% of patients with coronary heart disease, respectively.
Dyslipidemia guidelines recommend a staged approach based
on risk stratification and the early identification and effective
management of high-risk patients to tailor the intensity of LDL-
C management (Catapano et al., 2016). In Milano metropolitan
area, which serves approximately 1,400,000 residents, CV disease
was in 2013 the first cause of death in women (34.4%) and
the second in men (29.5%) and a leading cause of hospital
admission (standardized rates 25/1,000 in men and 15/1,000 in
women). From the Local Health Authority database, proportions
ofMilano residents with overt CV disease or diabetes were 10.4%,
3.6% among 40–64 years old subjects and 38% and 11% among
those >65 years, respectively. Of local residents with laboratory
tests performed, 28% self-reported hypercholesterolemia; of these
24% were on drug therapy as compared to the 29% national
Italian rate.
ASST Great Metropolitan Hospital Niguarda (NIG) is a
tertiary referral center with wide outreach. The catchment
area of its biochemistry laboratory is largely coincident with
Milano Local Health Authority District 24, with a population
of 350,000 residents. Over 2,000 patients were admitted for a
CV event or procedure at NIG in 2014. Based on the above
2Use of medicines in Italy - The OSMED report 2014 AIFA Italian Medicines
Agency http://www.agenziafarmaco.gov.it/it/content/luso-dei-farmaci-italia-
rapporto-osmed-2014
3www.cuore.iss.it
4Milan Local Health Authority Health Services Programming Coordination
Document 2015. https://www.ats-milano.it
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FIGURE 1 | SKIM-LEAN project design. TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; EHR, electronic
health records; CV, cardiovascular; GP, general practitioner.
data, we estimated that over 50,000 patients in NIG catchment
area might benefit from cholesterol-lowering agents, whereas
in the primary prevention setting, given estimated prevalence
rates of 1:200 to 1:500 of familial hypercholesterolemia in the
literature, 700–1.750 FH subjects may live in NIG catchment
area.
SKIM LEAN was devised to exploit the potential of electronic
health records (EHRs) stored at a large metropolitan hospital.
The general objective of SKIM LEAN is to implement the
systematic integration of knowledge derived from routine
laboratory tests with background analysis of EHR clinical
databases for the identification and appropriate early referral
to specialist care of patients with hypercholesterolemia, who
may be inadequately controlled according to their CV risk level.
SKIM LEAN will risk-stratify subjects undergoing lipid testing
at biochemistry laboratory, to alert their GPs for abnormal
values, and to offer specialist advice on lipid management if
appropriate.
Furthermore, SKIM LEAN aims at improving health
professionals’ competence and patient empowerment, as well
as implementing a hospital-community shared care pathway to
increase the rate of patients who achieve LDL-C targets.
SKIM LEAN is composed of a retrospective epidemiological
analysis phase and a prospective shared care pathway
interventional phase.
The aim of the first retrospective phase was to stratify patients
in CV risk categories, to identify subjects with possible FH or
patients with a previous atherosclerotic CV event (secondary
prevention) (i.e., at very-high CV risk), and to assess the
discrepancy between ideal targets and the current concentration
of LDL-C observed in these subgroups. This paper describes
the strategies and methods used for the epidemiological
analysis and the implementation of the shared care pathway,
and reports the results obtained from data extracted
during 2016.
MATERIALS AND METHODS
All male and female subjects aged ≥ 18 years with laboratory
testing performed at NIG starting from 1/1/2016 were
retrospectively enrolled in the study.
The Ethical Committee Milano Area 3 of the ASST
Grande Ospedale Metropolitano Niguarda approved the
retrospective analysis of data extracted from hospital
database, and waived the need for further consent to be
obtained according to national data protection regulations
(Authorisation no. 9/2014—General Authorisation to Process
Personal Data for Scientific Research Purposes Published
in Italy’s Official Journal No. 301 of 30 December 20145;
written informed consent will be obtained from all research
5http://www.garanteprivacy.it/web/guest/home/docweb/-/docweb-display/export/
378607)
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participants when they attend the clinic for prospective
enrollment.
Study design is summarized in Figure 1.
The digital tool developed for the project has been
integrated into NIG Information System. All study information
flows occur through the web enterprise-wide intranet NIG
Clinical Portal. The Portal complies with requirements by
local regulations and Joint Commission standards as far
as data security, traceability, and user identification are
concerned.
Production databases includes laboratory test results from
the Laboratory Information System (LIS), EHR and admission-
discharge transfer (ADT). All extracted data of interest are
conveyed to the engine containing rules and correlation
algorithms that may be triggered through a user interface
accessible by the different actors involved.
Per each subject, data extraction starts from the LIS, which
collects and processes data from laboratory tests performed at
NIG. The LIS scans past examinations and, through a batch
Extract Transfer Load (ETL) procedure, drop selected datasets on
cases in an interchange database.
LIS data are integrated with selected clinical databases coming
from the EHR and ADT in NIG Clinical Portal to assess whether
patients had previous CV events, clinical modifiers for high
CV risk (diabetes, CKD, hypertension), or other comorbidity
potential secondary causes of hypercholesterolemia or conditions
that may pose a possible risk of adverse drug events, and in
addition to verify prescribed therapies.
Automated algorithms were built to extract such cases of
interest. The algorithm classifies subjects according to coded
diagnosis procedures and pharmacological therapy recorded
in the individual EHR within the previous 5 years (2011
to 2015). For those subjects who had no previous coded
diagnosis registered in the Clinical Portal, working diagnosis
reported on outpatient test prescription forms (mandatory for
Italian regulations) were used. Text mining was based on
Italian language terms, considering possible misspelled term
combinations.
When neither coded nor working diagnosis were available,
classification was attributed on the basis of the hospital unit were
blood samples were drawn.
Selection rules and coding algorithms for subjects
classification are shown in Table 1.
Subjects who according to the selection algorithms shown
in Table 1 did not fit in any risk category s or blood
donors (identified by the hospital unit “Immunohematology
TABLE 1 | Selection rules and coding algorithms to classify risk level of examined subjects.
1. Secondary
Prevention (previous
CV event)
1.1–Ischemic heart disease (IHD) ICD9CM code 410.xx to 414.xx. Working diagnosis text mining terms “INFART,”
“CAD,” “IMA,” “ISCHEM,” “ANGI,” “CORON,” “PTCA”
1.2–Cerebrovascular disease (CVD) ICD9CM code 433.xx to 437.xx. Working diagnosis text mining terms ICTUS,“
“CAROT,” “CEREB,” “ICA,” “TSA,” “TIA”
1.3–Peripheral vessel disease (PVD) ICD9CM code 440.2x Working diagnosis text mining terms “ANEURIS,” “AOCP,”
“ARTERIOP,” “VASCULOP,” “CLAUDICATIO,” “ATERO”
2. Excluded for
potentially secondary
hypercholesterolemia
2.1–HIV ICD9CM code 042, V08, 79571, 07953. Working diagnosis text mining terms “HIV,”
“IMMUNODE,” “ART,” “ACAVIR”
2.2–Hypothyroidism ICD9CM code 243, 244.xx, 245.xx. Working diagnosis text mining terms “IPOTIR“
2.3–Epilepsy ICD9CM code 345.xx. Working diagnosis text mining terms “EPIL”
2.4–Nephrotic syndrome ICD9CM code 581.xx
2.5–Organ transplant ICD9CM code V42, V420, V421, V426, V427, V428, V4281, V429. Working
diagnosis text mining terms “TX,” “TRAP,” “OLT”
2.6–Previous procedure as exclusion criterion ICD9CM code 312, 335.x, 336, 410.x
Drug therapy as exclusion criterion ATC D10BA01, H02, J05, N03
3. High risk Established 3.1-Diabetes ICD9CM code 250.xx. Working diagnosis text mining terms “DIAB,” “DM,” “GLICEM,”
“GLUC,” “MELLI,” “13”
3.2-Chronic kidney disease
(CKD)
ICD9CM code 580.xx, 582.xx, 583.xx, 585.xx, 586, 587. Working diagnosis text
mining terms “IRC,” “INSUF REN,” “DIALI,” “ED,” “NEFRIT,” “GMN”
3.3 -Hypertension ICD9CM code 401.xx to 405.xx. Working diagnosis text mining terms “IPERT”, “IPA”,
“IPART”, “PRESSOR”, “IA”
Putative 3.4-Dyslipidemia and Obesity ICD9CM code 272.xx, 278.xx. Working diagnosis text mining terms “DISL,” “DISPIL,”
“DISPLI,” “IPERCO,” “IPERLI,” “IPERTRI,” “COLEST,” “OBES,” “S
METABOL,”“DISMETAB,” “TRIGLI,” “LIPID,” “MALNUT ECCES,” “25”
3.5–Rheumatic diseases ICD9CM code 710.xx, 714.1, 714.2, 714.3x, 7200, 725. Working diagnosis text
mining terms “ARTRITE REUM,” “BECHET,” “BEHCET,” “SJOGREN,” “STRAUS,”
“CONNET,” “SCLERODERM,” “SCLERO SISTEM,” “AR,” “LUPUS”
3.6–Chronic hepatitis cirrhosis ICD9CM code 571.4x, 571.5, 571.6, 571.8, 571.9. Working diagnosis text mining
terms “EPATO CRON,” “EPATIT,” “HCV,” “HBV,” “NASH,” “ECA,” “STEAT,”
“CIRROSI,” “NAFLD,” “16”
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and transfusion medicine” code) were classified as “primary
prevention patients at low CV risk.”
Patients with more than one diagnosis were classified in
decreasing order of severity: e.g., a hypertensive subject who
had a history of CV event was categorized as secondary
prevention.
Data iteratively extracted from the different sources are
merged on the Clinical Portal study pages for individual
cases, in order to allow subsequent processing for referral
to the shared care pathway. Data for patients with LDL-C
>70 and <190 mg/dL and high CV risk and all those with
LDL-C ≥190 mg/dL were considered eligible for selection
to enter the prospective study. For this specific activity, the
algorithm allowed to drop subjects with LDL-C already at
target.
For all eligible subjects a patient page is made available on
the Clinical Portal dedicated section to allow review by clinical
investigators and confirmation of status.
On this page clinical investigators can:
◦ Access a case profile sheet merging key data from the above-
mentioned sources
◦ Navigate through past patients’ records stored on the Clinical
Portal EHRs
◦ Navigate through past patients’ medical reports through the
hospital clinical repository
◦ Delete from the lists cases classified as “not interesting” by the
selection algorithm
◦ Validate high-risk cases proposed by the algorithm for alerting
the GP
FIGURE 2 | SKIM-LEAN data flow for the period January–December 2016. CKD, chronic kidney disease.
FIGURE 3 | Gender distribution by age categories.
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◦ Classify relevant cases for further investigation by the GP
◦ Fill-in administrative patient data (as, e.g., GP contacts) if the
system detects missing information.
Alerts for GPs are generated in a standardized report format for
those patients who are judged to have inappropriately high LDL-
C for their CV risk level, and might potentially need a specialist
referral to NIG outpatient secondary prevention clinic or lipid
clinic.
The report is posted through the Regional Health System
Repository in patients’ individual EHR and an alert email for GPs
is automatically generated. Two links are embedded in the report.
The former points to the hospital web-page detailing SKIM
LEAN project objectives and processes, so that GPs can always
refresh their knowledge on SKIM LEAM and decide whether they
consider specialist referral appropriate for the specific patient.
The latter link allows GPs to register the patient’s consent and
willingness to access the prospective shared-care pathway. GPs
responses update the patients’ status on the SKIM LEAN page in
the Clinical Portal, where a list is generated for visit booking by
personnel at the hospital clinics.
EVALUATION OF PRACTICE
IMPROVEMENT OBJECTIVES
Systematic and repetitive processing of NIG laboratory test
results during project year 2 will allow to assess changes in rates
FIGURE 4 | LDL-C distribution by gender.
FIGURE 5 | LDL-C distribution by age categories.
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of uncontrolled hypercholesterolemia at the population level for
all the subjects who undergo LDL-C testing, and treatment and
patient-level changes in LDL-C targets for those patients who
enter the care pathway.
Specific metrics for practice improvement objectives are:
- Proportion of secondary prevention patients who achieve
LDL-C < 100 mg/dl or a >50% decrease in LDL-C (primary
outcome end point).We calculated that, based on national and
literature data (Poli et al., 2011) and an estimated drop-out
rate of 40% (non-referral by GP, or patient refusal, or patient
decline to repeat follow-up LDL-C), 550 secondary prevention
patients should be selected to detect an absolute 10% points
increase (from 50 to 60%) in the above metric with 80% power
and alpha 0.05.
- Increase in the overall proportion of patients with LDL-C
<100 mg/dl from baseline to end of study data extraction
(secondary end point): 1500 patients with follow-up LDL-C
tests will allow to detect an absolute 5% points increase (from
40 to 45%) in this metric with 80% power and alpha 0.05.
- Absolute/percent change in individual cholesterol levels for
all patients who have follow-up lab tests from the first to the
second study year.
Retrospective Epidemiological Analysis of
2016 Data
Based on the detailed criteria described in the method section,
data from 25,116 patients with tests charged to the Regional
Health service during 2016 and at least one valid LDL-C result
available were identified. The enrolment flow is depicted in
Figure 2.
Consistently with well-known demographic trends, the
proportion of female subjects significantly increased with age
(p < 0.0001) (Figure 3)
Furthermore, a significant imbalance in LDL-C distribution
across genders was observed, with a significantly greater
prevalence of women in the higher LDL-C classes (p < 0.0001,
Figure 4).
As for LDL-C level distribution with age, prevalence of
uncontrolled LDL-C concentrations was significantly higher
among middle-aged subjects when compared to younger and
older patients (p < 0.0001, Figure 5).
SKIM LEAN focuses on the identification of subjects at high
or very high CV risk to assess whether their LDL-C levels comply
with personalized targets. Figure 6 shows that only one fourth of
secondary prevention patients achieved the recommended target
of <70 mg/dl, while among patients at high CV risk, levels below
100 mg/dl were observed in 51% of diabetics, 41% of patients
with CKD, and 27% of hypertensive subjects. Conversely, among
healthy blood donors at low CV risk, one half had LDL-C levels
above 115 mg/dl.
DISCUSSION
The importance of hypercholesterolemia as a contributor to CV
morbidity and mortality has long been known. Strategies for
effective CVD prevention should be three-tiered. A decrease
in the average cholesterol levels in the general population
through lifestyle interventions and regulatory actions on the
composition of processed foods may have huge impacts. In
routine clinical practice this activity is typically carried out at the
primary care setting and implies counseling on healthy lifestyle
choices, that should start from childhood and be reinforced
throughout adulthood. The second key CVD prevention activity
is the identification of subjects at a higher risk of CVD
events for comprehensive and intensive risk factor management.
Routine laboratory testing offers the opportunity to spot subtle
FIGURE 6 | Proportion of patients at LDL-C targets (detached segments) according to their risk category. GFR, glomerular filtration rate.
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abnormalities in lipid and glucose profiles or renal function that
may substantially impact on individual risk and should never
be overlooked. The third key preventive activity, reducing risk
in people with established CVD through therapies aimed at
decreasing lipid levels, requires sustained clinical engagement
since strict targets may not be easily achieved.
Epidemiological studies and surveys continue to document
insufficient LDL-C control at all levels and highlight pitfalls in
current hyperlipidemia management strategies. Our preliminary
results in the large unselected population examined at NIG,
a reference metropolitan hospital, confirm these findings and
support the potential value of an intervention that is scalable to
other settings and geographic locations.
Barriers to effective lipid management in clinic include a lack
of focus on the global CV risk concept, insufficient awareness
of appropriate targets relative to the individual patient’s risk,
inadequate knowledge of the therapeutic tools, and lack of
confidence in personal treatment skills (Kwok et al., 2016).
Therapeutic inertia is particularly worrisome in patients with
established CVD, since over half of them may require the use of
high-efficacy cholesterol-lowering medications (Poli et al., 2011).
The current use of administrative databases to identify
patients from administrative coding, ordered tests and drug
prescription refill, leaves important knowledge gaps, since LDL-C
levels may not be properly appraised. The systematic exploitation
of existing health care data holds a great potential to improve
collaborative care.
Specialist support in the transfer of knowledge and in setting-
up personalized drug treatment for complex cases represent
powerful levers to improve dyslipidemia management in primary
care. A shared care pathway will also reinforce patients’ trust in
physicians’ sense of control of their health problem.
The main strength of SKIM LEAN is the automated iterative
patient selection routine based on EHR processing which will
seamlessly bring to medical attention those patients who most
benefit from strict control of cholesterol, and will consolidate
interactions among hospital specialists and community health
professionals to foster high-quality patient care.
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